Skip to main content
. 2018 Oct 6;8(19):5200–5212. doi: 10.7150/thno.27806

Figure 2.

Figure 2

Down-regulation of OGT enhances cisplatin resistance in ovarian cancer cell lines. (A) A2780 and SKOV3 were transfected with control or OGT shRNA to establish stable OGT-deficient cell lines. Western blotting was used to test the expression of OGT in control and OGT-deficient cells. (B-C) Control and OGT-deficient cells were treated with different concentrations of cisplatin for 48 h. The cell viability of A2780 (B) and SKOV3 (C) were measured by CCK-8 after cisplatin treatment. (D) Control and OGT-deficient cells were treated with cisplatin (5 µg/mL) for 24 h. Apoptotic cells were measured by ANXA5 and PI staining. The numbers shown are the sum of ANXA5-positive and double-positive cells. (E-F) Control and OGT-deficient cells were treated with different concentrations of paclitaxel for 48 h. The cell viability of A2780 (E) and SKOV3 (F) were measured by CCK-8 after paclitaxel treatment. (G) Control and OGT-deficient cells were treated with paclitaxel (100 nM) for 24 h. Apoptotic cells were measured by ANXA5 and PI staining. The numbers shown are the sum of ANXA5-positive and double-positive cells. The values are presented as a mean ± SD (n = 3). **P < 0.01, *P < 0.05.